In vivo induction of the interferon-stimulated protein 2'5'- oligoadenylate synthetase in tumor and peripheral blood cells during IFN-α treatment of metastatic melanoma

Journal of Interferon and Cytokine Research

Volumn 18, Issue 9, 1998, Pages 691-695

  Grandér, Dan ^a   Sangfelt, Olle ^a   Skoog, Lambert ^a   Hansson, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPIRATION BIOPSY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0031720137     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.691     Document Type: Article

References (35)

1. EINHORN, S., and STRANDER, H. (1993). Interferon treatment of human malignancies - a short review. Med. Oncol. Tumor Pharmacother. 10, 25-29.
2. LEGHA, S.S. (1997). The role of interferon alpha in the treatment of metastatic melanoma. Semin. Oncol. 24 (Suppl. 4), S24-31.
3. PYRHÖNEN, S., HAHKA-KEMPPINEN, M., and MUHONEN, T. (1992). A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J. Clin. Oncol. 10, 1919-1926.
4. KEILHOLZ, U., SCHEIBENBOGEN, C., STOELBEN, E., SAEGER, H.D., and HUNSTEIN, W. (1994). Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. Eur. J. Cancer 30A, 955-958.
5. KIRKWOOD, J.M., STRAWDERMAN, M.H., ERNSTOFF, M.S., SMITH, T.J., BORDEN, E.C., and BLUM, R.H. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7-17.
6. GRANDÉR, D., SANGFELT, S., and ERICKSON, S. (1997). How does interferon exert its cell growth inhibitory effect? Eur. J. Heamatol. 59, 129-135.
7. GRESSER, I., KAIDO, T., MAURY, C., WOODROW, D., MOSS, J., and BELARDELLI, F. (1994). Interaction of IFN alpha/beta with host cells essential to the early inhibition of Friend erythroleukemia visceral metastases in mice. Int. J. Cancer 57, 604-611.
8. FOLKMAN, J. (1992). Angiogenesis. J. Biol. Chem. 267, 10931-10934.
9. VAN DEN HOOF, A. (1988). Stromal involvement in malignant growth. Adv. Cancer Res. 50, 159-196.
10. GRANDÉR, D., ÖBERG, K., LUNDQVIST, M.-L., TIENSUU JANSSON, E., ERIKSSON, B., and EINHORN, S. (1990). Interferon-induced enhancement of 2′,5′-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet 336, 337-337.
11. ROSENBLUM, M.G., MAXWELL, B.L., TALPAZ, M., KELLEHER, P.J., McCREDIE, K.B., and GUTTERMAN, J.U. (1986). In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2′,5′-oligoadenylate synthetase. Cancer Res. 46, 4848-4852.
12. TALPAZ, M., ROSENBLUM, M., KURTZROCK, R., REUBEN, J., KANTARJIAN, H., and GUTTERMAN, J. (1987). Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia - a pilot study. Am. J. Hematol. 24, 341-350.
13. FERBUS, D., KHOSRAVI, S., DUMONT, J., and BILLARD, C. (1990). In vivo and in vitro induction of 2′,5′-oligoadenylate synthetase by interferon-alpha in nodular non-Hodgkin's lymphoma and correlations with the clinical response. J. Biol. Regul. Homeostat. Agents 4, 127-134.
14. BRENNING, G., ÅHRE, A., and NILSSON, K. (1985). Correlation between in vitro and in vivo sensitivity to human leukocyte interferon in patients with multiple myeloma. Scand. J. Haematol. 35, 543-549.
15. GRANDÉR, D., SKOOG, L., TANI, E., and EINHORN, S. (1992). Measurement of interferon sensitivity in tumor cells from fine needle aspiration biopsies. Eur. J. Cancer 28A, 815-818.
16. WHO Handbook for Reporting Results of Cancer Treatment. (1979). Geneva: World Health Organization.
17. SANGFELT, O., ÖSTERBORG, A., GRANDËR, D., ANDERBRING, E., ÖST, Å., MELLSTEDT, H., and EINHORN, S. (1995). Response to interferon therapy in patients with multiple myeloma correlates with the expression of the Bcl-2 oncoprotein. Int. J. Cancer 63, 190-192.
18. EINHORN, S., ÅHRE, A., BLOMGREN, H., JOHANSSON, B., MELLSTEDT, H., and STRANDER, H. (1982). Interferon and natural killer cell activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer cell activity and clinical response to human interferon-α. Int. J. Cancer 30, 167-172.
19. LANE, H.C., FEINBERG, J., DAVEY, V., DEYTON, L., BASELER, M., MANISCHEWITZ, J., MASUR, H., KOVACS, J., HERPIN, B., WALKER, R., METCALF, J., SALZMAN, N., QUINNAN, G., and FAUCI, A.S. (1988). Anti-retroviral effects of interferon-α in AIDS-associated Kaposi's sarcoma. Lancet 26, 1218-1222.
20. EINHORN, S., VANKY, F., GRANDÉR, D., and WILLEMS, J.S. (1987). Induction of 2′-5′-oligoadenylate synthetase in freshly separated malignant cells from solid tumors. Variability in the susceptibility to interferon. Eur. J. Cancer 23, 1607-1613.
21. WONG, L.H., KRAUER, K., HATZINISARIOU, I., ESTCOURT, M.J., HERSEY, P., TAM, N.D., EDOMONDSON, S., DEVENISH, R.J., and RALPH, S.J. (1997). Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2 and p48-ISGF3γ. J. Biol. Chem. 272, 28779-28785.
22. WONG, L.H., KRAUER, K., HATZINISARIOU, I., DEVENISH, R.J., and RALPH, S.J. (1995). The mechanism of resistance to interferons in melanoma cells: deficiency in signalling at the level of interferon-activated transcription factors. J. Interferon Cytokine Res. 15, 172.
23. DANIEL, S.K., PINE, R., PFEFFER, L.M., LEVY, D.E., and DARNELL, J.E. (1988). Cells resistant to interferon are defective in activation of a promoter-binding factor. EMBO J. 7, 3779-3783.
24. XU, B., GRANDÉR, D., SANGFELT, O., and EINHORN, S. (1994). Primary leukemia cells resistant to α-interferon in vitro are defective in the induction of the DNA-binding factor ISGF-3. Blood 84, 1942-1949.
25. MATIKAINEN, S., RONNI, T., HURME, M., PINE, R., and JULKUNEN, I. (1996). Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood 88, 114-123.
26. EISENHAUER, R.A., LIPPMAN, S.M., and KAVANAGH, J.J. (1994). Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia 8(Suppl 3), S38-41.
27. TRIOZZI, P.L., WALKER, M.J., PELLEGRINI, A.E., and DAYTON, M.A. (1996). Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest. 14, 293-298.
28. FIERLBECK, G., SCHREINER, T., and RASSNER, G. (1995). Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma. Cancer Immunol. Immunother. 40, 157-164.
29. SANGFELT, O., ERIKSSON, S., EINHORN, S., and GRANDÉR, D. (1997). Induction of Cip/Kip and Ink4 cyclin-dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene 14, 415-423.
30. SANGFELT, O., ERICKSON, S., CASTRO, J., HEIDEN, T., EINHORN, S., and GRANDÉR, D. (1997). Induction of apoptosis and inhibition of cell growth are independent responses to interferon-α in hematopoietic cell lines. Cell Growth Differ. 8, 343-352.
31. AHRE, A., BJÖRKHOLM, M., ÖSTERBORG, A., BRENNING, G., GAHRTON, G., GYLLENHAMMAR, H., HOLM, G., JOHANSSON, B., JULIUSSON, G., JÄRNMARK, L., KILLANDER, A., LERNER, R., LOCKNER, D., NILSSON, B., SIMONSSON, B., STALFELT, A.-M., STRANDER, H., SMEDMYR, B., SVEDMYR, E., UDÉN, A.-M., WADMAN, B., WEDELIN, C., and MELLSTEDT, H. (1988). High doses of natural alpha-interferon in the treatment of multiple myeloma - a pilot study from the myeloma group of central Sweden. Eur. J. Hematol. 41. 123-130.
32. KIRKWOOD, J., HARRIS, J., VERA, R., SANDLER, S., FISCHER, D., KHANDEKAR, J., ERNSTOFF, M., GORDON, L., LUTES, R., BONOMI, P., LYTTON, B., COBLEIGH, M., and TAYLOR, S. (1985). A randomized study of low and high doses of leukocyte α-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 45, 863-871.
33. VAN DER MOLEN, L., DUFFEY, P., and URBA, W. (1989). Low dose vs high dose recombinant interferon α-2a treatment in favorable histology non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. 8, 255.
34. INK4 gene. Response to interferon-α therapy in one of the subclones. Leukemia 10, 909-924.
35. ALMASRI, A.N., WERFEL, T., JAKSCHIES, D., and VON WUSSOW, P. (1997). Intracellular staining of mx proteins in cells from peripheral blood, bone marrow and skin. Mol. Pathol. 50, 9-14.